Actinium Pharmaceuticals Inc (ATNM)
$7.82
Performance
- $7.72$8.08$7.82
1.27%
Downside
Day's Volatility :4.45%
Upside
3.22%
- $4.00$10.24$7.82
48.85%
Downside
52 Weeks Volatility :60.94%
Upside
23.63%
Returns
| Period | Actinium Pharmaceuticals Inc | Index (Russel 2000) |
|---|---|---|
3 Months | 14.99% | 0.0% |
6 Months | 41.07% | 0.0% |
1 Year | 12.54% | 0.0% |
3 Years | 14.83% | -20.2% |
Highlights
Market Capitalization | 230.5M |
Book Value | $1.49 |
Earnings Per Share (EPS) | -1.71 |
PEG Ratio | 0.0 |
Wall Street Target Price | 25.4 |
Profit Margin | 0.0% |
Operating Margin TTM | -61645.68% |
Return On Assets TTM | -32.78% |
Return On Equity TTM | -91.92% |
Revenue TTM | 81.0K |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | 1.0M |
EBITDA | -49.7M |
Diluted Eps TTM | -1.71 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.53 |
EPS Estimate Next Year | -0.45 |
EPS Estimate Current Quarter | -0.52 |
EPS Estimate Next Quarter | -0.55 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 224.81%
Technicals Summary
Sell
Neutral
Buy
Actinium Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Actinium Pharmaceuticals Inc | 7.19% | 41.07% | 12.54% | 14.83% | 5.25% |
 Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
 Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
 Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
 Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Actinium Pharmaceuticals Inc | NA | NA | 0.0 | -1.53 | -0.92 | -0.33 | NA | 1.49 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Actinium Pharmaceuticals Inc | Buy | $230.5M | 5.25% | NA | 0.0% |
Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Actinium Pharmaceuticals Inc
Decreasing Revenue
Revenue is down for the last 2 quarters, 114.0K → 81.0K (in $), with an average decrease of 29.0% per quarter
Increasing Net Profit
Netprofit is up for the last 4 quarters, -15.18M → -8.67M (in $), with an average increase of 21.4% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 49.1%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 171.7%
Company Information
actinium pharmaceuticals, inc. (www.actiniumpharma.com) (nyse mkt: atnm) is a new york-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. the company’s lead radiopharmaceutical iomab™-b will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. the company is preparing a single, pivotal, multicenter phase 3 clinical study of iomab™-b in refractory and relapsed acute myeloid leukemia (aml) patients over the age of 55 with a primary endpoint of durable complete remission. the company’s second program, actimab-a, is continuing its clinical development in a phase 1/2 trial for newly diagnosed aml patients o
Organization | Actinium Pharmaceuticals Inc |
Employees | 49 |
CEO | Mr. Sandesh C. Seth M.B.A., M.S. |
Industry | Health Technology |
Discover More
A Spac I Acquisition Corp
$7.82
-1.01%
Keyarch Acquisition Corp
$7.82
-1.01%
Connexa Sports Technologies Inc
$7.82
-1.01%
Us Value Etf
$7.82
-1.01%
First Wave Biopharma Inc
$7.82
-1.01%
Global X Msci Next Emerging
$7.82
-1.01%
Fat Projects Acquisition Corp
$7.82
-1.01%
Capital Link Global Fintech
$7.82
-1.01%
Applied Uv Inc
$7.82
-1.01%